Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - entrectinibum - gélules - entrectinibum 100 mg, lactosum 65 mg, cellulosum microcristallinum, acidum tartaricum, hypromellosum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 132, pro capsula. - solide tumoren, nicht-kleinzelliges bronchialkarzinom (nsclc) - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - entrectinibum - gélules - entrectinibum 200 mg, lactosum 130 mg, cellulosum microcristallinum, acidum tartaricum, hypromellosum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 110 0.5543 mg, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 132, pro capsula. - solide tumoren, nicht-kleinzelliges bronchialkarzinom (nsclc) - synthetika

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - agents antinéoplasiques - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Canada - français - Health Canada

hoffmann-la roche limited - entrectinib - capsule - 100mg - entrectinib 100mg - antineoplastic agents

Canada - français - Health Canada

hoffmann-la roche limited - entrectinib - capsule - 200mg - entrectinib 200mg - antineoplastic agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - itraconazolum - capsules - itraconazolum 100 mg, hypromellosum, macrogolum 20'000, sacchari sphaerae ut saccharum 175.68 mg et maydis amylum, kapselhülle: gelatina, e 127, e 132, e 171 pro capsula. - antimykotikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - itraconazolum - capsules - itraconazolum 100 mg, hypromellosum, macrogolum 20'000, sacchari sphaerae ut saccharum 175.68 mg et maydis amylum, kapselhülle: gelatina, e 127, e 132, e 171 pro capsula. - vulvovaginalcandiosis - synthetika

Canada - français - Health Canada

janssen inc - itraconazole - solution - 10mg - itraconazole 10mg - azoles

Canada - français - Health Canada

janssen inc - itraconazole - capsule - 100mg - itraconazole 100mg - azoles

Canada - français - Health Canada

jamp pharma corporation - itraconazole - solution - 10mg - itraconazole 10mg - azoles